Table 3 Univariate and multivariate analyses of the clinical characteristics related to the prognosis of de novo stage IV (dnIV) breast cancer for the Non-surgery group

Subtype:

0.64

 Luminal

46 (57.5%)

 Luminal Her2

9 (11.3%)

 Her2

10 (12.5%)

 Triple negative

14 (17.5%)

Histology:

0.45

 IDC

73 (91.3%)

 ILC

5 (6.25%)

Metastasis status:

0.99

 Oligo

36 (59%)

 Visceral

66 (82.5%)

Systemic therapy:

< 0.0001

0.0006

 Chemotherapy

29 (36/7%)

 Endocrine therapy

27 (34.2%)

 C + E

17 (21.5%)

 None

6 (7.59%)

Best therapeutic response:

0.0012

0.0018

 CR

1 (1.32%)

 PR

8 (10.5%)

 SD

4 (5.3%)

 PD

42 (55.3%)

cN:

0.25

< 0.0001

 0

5

 1

34

 2

15

 3

21

Pre ALC, /µL:

0.19

0.410

 >1500

32

 ≤1500

33

6-month ALC:

0.026

0.201

 >1500

16

 ≤1500

21

1-year ALC:

0.007

0.662

 >1500

15

 ≤1500

11

Pre NLR:

0.52

 >3

15

 ≤3

11

6-month NLR:

0.05

0.025

 >3

12

 ≤3

25

1-year NLR:

0.001

0.0005

 >3

5

 ≤3

21